Pretransplant Antiviral Choice

Hepatitis C in Renal Disease, Hemodialysis and Transplantation

This flow traces the debate over whether HCV should be eradicated before Kidney transplantation despite treatment toxicity and waiting-list delay.

increasing

Bearing strength in each event

decreasing

Treatment Opportunity Treatment Opportunity from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Treatment Opportunity

Treatment Opportunity

Ribavirin Constraint Ribavirin Constraint from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Ribavirin Constraint

Ribavirin Constraint

Clearance Before Graft Clearance Before Graft from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Clearance Before Graft Durable response A Sustained virologic response before transplantation is usually maintained after immunosuppression.

Clearance Before Graft from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Clearance Before Graft Durable response A Sustained virologic response before transplantation is usually maintained after immunosuppression.

Clearance Before Graft Durable response A Sustained virologic response before transplantation is usually maintained after immunosuppression. It may also reduce posttransplant HCV-related glomerulonephritis and metabolic complications. An unresolved cost Treatment can delay transplantation and exclude nonresponders from some opportunities. The preferred strategy is therefore biologically attractive but socially and clinically unevenly available.

during dialysis before transplantation

during antiviral treatment in End-stage renal disease

immediately before transplantation